<?xml version="1.0" encoding="UTF-8"?>
<p>Regarding ω-6 PUFA, although they are associated with possible increased inflammatory conditions, being arachidonic acid a presursor of proinflammatory prostanoids, such a risk is not confirmed by clinical evidence [
 <xref rid="B200-vaccines-08-00468" ref-type="bibr">200</xref>]. Indeed, studies in healthy human adults highlighted that an increased intake of these fatty acids did not induce inflammation; conversely, epidemiological evidence reported reduced inflammatory conditions [
 <xref rid="B200-vaccines-08-00468" ref-type="bibr">200</xref>]. The antinflammatory effects of LA have been reported too [
 <xref rid="B193-vaccines-08-00468" ref-type="bibr">193</xref>]. Similarly, increased LA intake was found to be not related to increased amounts of ARA and proinflammatory factors; however, an inverse correlation with EPA and DHA was reported [
 <xref rid="B201-vaccines-08-00468" ref-type="bibr">201</xref>]. This suggests that the interaction between ω-e and ω-6 series is regulated by complex mechanisms that requires further clarifications.
</p>
